Intravenous Lidocaine for Laparoscopic Cholecystectomy

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Intravenous lidocaine has been shown to have analgesic, antinflammatory, antihyperalgesic, antithrombotics and neuroprotective properties. In a previous study conducted in patients undergoing laparoscopic cholecystectomy under general anesthesia with desflurane and fentanyl, intraoperative i.v. infusion of lidocaine spared opioids consumption in the recovery room by 30%.

The purpose of this study was to determine if an i.v. infusion of lidocaine without intraoperative opioids would reduce the amount of fentanyl to the same extent and opioids-related side effects.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre
• Treatments: Fentanyl; Lidocaine

Criteria

Inclusion Criteria:

• patients undergoing laparoscopic cholecystectomy

Exclusion Criteria:

• age <18 yr or > 85 yr,

• ASA physical status 3 and greater, history of hepatic failure (Child & Pug A-C),

• renal failure (creatinine outside the normal range) or cardiac failure (NYHA I-IV),

• Adams-Stoke syndrome,

• severe degrees of sinoatrial, atrioventricular or intraventricular block,

• organ transplant,

• diabetes mellitus type 1 and 2,

• morbid obesity (BMI > 40),

• chronic use of opioids and beta-blockers,

• known seizures,

• severe mental impairment,

• allergy to local anesthetics and to all the medications used in the study, or

• inability to understand pain assessment.